Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344642 | 1.00 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPROKR1 | |
| SCHEMBL27211435 | 0.86 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29457541 | 0.86 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| Trifluoroacetic Acid SCHEMBL29457433 | 0.74 | HTR2A (0.46) | PIK3CDPIK3CA | |
| Trifluoroacetic Acid SCHEMBL30473673 | 0.74 | HTR2A (0.46) | PIK3CDPIK3CA | |
| SCHEMBL25341741 | 0.74 | HTR2A (0.55) | — | |
| SCHEMBL23326185 | 0.74 | HTR2A (0.55) | PROKR1 | |
| SCHEMBL25344277 | 0.70 | PIK3CD (0.51) | PIK3CDPIK3CAPROKR1 | |
| SCHEMBL30473674 | 0.70 | PIK3CD (0.51) | PIK3CDPIK3CAPROKR1 | |
| SCHEMBL27211356 | 0.70 | PIK3CD (0.51) | PIK3CDPIK3CAPROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | PIK3CD 4261/4885PIK3CA 4494/4885PIK3CB 4376/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | PIK3CD 4261/4885PIK3CA 4494/4885PIK3CB 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.